Compare SM Energy Company Common Stock (SM) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SM Energy Company Common Stock vs Spyre Therapeutics Inc. Common Stock — how do they compare? SM Energy Company Common Stock trades at $38.06 (market cap $9.17B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: SM Energy Company Common Stock is the larger of the two by market cap, and SM Energy Company Common Stock pays a 2.28% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold SM Energy Company Common Stock for 2 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SM | SYRE | |
|---|---|---|
Market Cap | $9.17B | $7.52B |
Volume | 2,026,791 | 1,441,031 |
Sector | Energy | Health |
52-Week High | $41.29 | $108.92 |
52-Week Low | $17.57 | $22.18 |
Typical Hold Time | 2 Days | 0 Days |
Enterprise Value | $15.58B | $6.52B |
Dividend Yield | 2.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SM Energy (SM) trades at $38.54, up 2.26% with strong bullish technical signals and consistent earnings beats. The stock shows robust fundamentals with a low P/E of 6.83, healthy profit margins above 19%, and positive cash flow generation. Recent analyst coverage remains overwhelmingly positive with 65% buy ratings and a $39.08 consensus target, slightly above current levels.
Outlook remains favorable given strong earnings momentum and attractive valuation metrics, though overbought RSI readings suggest near-term consolidation risk. The company's upcoming Q3 2026 earnings report on November 3rd represents the next key catalyst for price movement.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About SM Energy Company Common Stock
SM Energy is an independent oil and natural gas exploration and production company. Its operations include the Permian, Maverick, Uinta, and Denver-Julesburg basins.
Read more on SM →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
